Australia Square
Level 14 264-278 George Street
Sydney, NSW 2000
Australia
61 2 8607 5124
https://www.nextscience.com
Sector(s): Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Full-time employees:
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Mr. Harry Thomas Hall | MD, CEO & Director | 639.89k | N/A | N/A |
Dr. Matthew Franco Myntti | Founder & CTO | 563.6k | N/A | N/A |
Marc Zimmerman | Chief Financial Officer | 525.11k | N/A | N/A |
Mr. Jon Swanson | Chief Operating Officer | 405.86k | N/A | N/A |
Mr. Robert Bell | Senior Vice President of North American Sales | N/A | N/A | N/A |
Ms. Gillian Maria Nairn AGIA, B.A., BA, L.L.B., L.L.M., LLB, LLM, MAICD | Company Secretary | N/A | N/A | N/A |
Next Science Limited, a medical technology company, researches, develops, and commercializes technologies that address the issues in human health caused by biofilms in the United States and Australia. The company develops its products using Xbio Technology platform. It offers SURGX, an antimicrobial gel designed for postoperative wound; BACTISURE, a wound lavage that is used to remove biofilm; BlastX, an antimicrobial wound gel that provides wound management by maintaining a moist wound environment, which is conducive to wound healing; and XPERIENCE for use in cleansing and removal of debris, including microorganisms from wounds. The company was founded in 2012 and is headquartered in Sydney, Australia.
Next Science Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.